JP7570342B2 - 眼の疾患又は障害を治療するための医薬組成物 - Google Patents

眼の疾患又は障害を治療するための医薬組成物 Download PDF

Info

Publication number
JP7570342B2
JP7570342B2 JP2021552571A JP2021552571A JP7570342B2 JP 7570342 B2 JP7570342 B2 JP 7570342B2 JP 2021552571 A JP2021552571 A JP 2021552571A JP 2021552571 A JP2021552571 A JP 2021552571A JP 7570342 B2 JP7570342 B2 JP 7570342B2
Authority
JP
Japan
Prior art keywords
depot
therapeutic agent
pharmaceutical composition
lactide
biodegradable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021552571A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022523548A (ja
JPWO2020181060A5 (enExample
Inventor
クマール ダス、サンジブ
リン、チェン－ウェン
Original Assignee
アエリエ ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アエリエ ファーマシューティカルズ インコーポレイテッド filed Critical アエリエ ファーマシューティカルズ インコーポレイテッド
Publication of JP2022523548A publication Critical patent/JP2022523548A/ja
Publication of JPWO2020181060A5 publication Critical patent/JPWO2020181060A5/ja
Priority to JP2024176401A priority Critical patent/JP2025004161A/ja
Priority to JP2024176400A priority patent/JP2025004160A/ja
Application granted granted Critical
Publication of JP7570342B2 publication Critical patent/JP7570342B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polyamides (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Biological Depolymerization Polymers (AREA)
JP2021552571A 2019-03-05 2020-03-05 眼の疾患又は障害を治療するための医薬組成物 Active JP7570342B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024176401A JP2025004161A (ja) 2019-03-05 2024-10-08 眼の疾患又は障害を治療するための医薬組成物
JP2024176400A JP2025004160A (ja) 2019-03-05 2024-10-08 眼の疾患又は障害を治療するための医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962814198P 2019-03-05 2019-03-05
US62/814,198 2019-03-05
PCT/US2020/021136 WO2020181060A1 (en) 2019-03-05 2020-03-05 Pharmaceutical compositions for treating ocular diseases or disorders

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2024176400A Division JP2025004160A (ja) 2019-03-05 2024-10-08 眼の疾患又は障害を治療するための医薬組成物
JP2024176401A Division JP2025004161A (ja) 2019-03-05 2024-10-08 眼の疾患又は障害を治療するための医薬組成物

Publications (3)

Publication Number Publication Date
JP2022523548A JP2022523548A (ja) 2022-04-25
JPWO2020181060A5 JPWO2020181060A5 (enExample) 2023-03-08
JP7570342B2 true JP7570342B2 (ja) 2024-10-21

Family

ID=72337143

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021552571A Active JP7570342B2 (ja) 2019-03-05 2020-03-05 眼の疾患又は障害を治療するための医薬組成物
JP2024176400A Pending JP2025004160A (ja) 2019-03-05 2024-10-08 眼の疾患又は障害を治療するための医薬組成物
JP2024176401A Pending JP2025004161A (ja) 2019-03-05 2024-10-08 眼の疾患又は障害を治療するための医薬組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024176400A Pending JP2025004160A (ja) 2019-03-05 2024-10-08 眼の疾患又は障害を治療するための医薬組成物
JP2024176401A Pending JP2025004161A (ja) 2019-03-05 2024-10-08 眼の疾患又は障害を治療するための医薬組成物

Country Status (10)

Country Link
US (1) US12478577B2 (enExample)
EP (1) EP3934646A4 (enExample)
JP (3) JP7570342B2 (enExample)
KR (1) KR20210135560A (enExample)
CN (3) CN118304422A (enExample)
AU (1) AU2020232314C1 (enExample)
BR (1) BR112021017436A2 (enExample)
CA (1) CA3132635A1 (enExample)
MX (2) MX2021010599A (enExample)
WO (1) WO2020181060A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118304422A (zh) 2019-03-05 2024-07-09 爱瑞制药公司 用于治疗眼部疾病或病症的药物组合物
CA3166738A1 (en) 2020-02-06 2021-08-12 Charles D. Blizzard Travoprost compositions and methods for treating ocular diseases
CA3171563A1 (en) 2020-03-25 2021-09-30 Charles D. Blizzard Ocular implant containing a tyrosine kinase inhibitor
WO2021207486A1 (en) * 2020-04-08 2021-10-14 Aerie Pharmaceuticals, Inc. Treatments
IL307997A (en) 2021-04-30 2023-12-01 Perfuse Therapeutics Inc Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases
WO2022235906A1 (en) 2021-05-05 2022-11-10 Aerie Pharmaceuticals, Inc. Pharmaceutical preparation
TW202448436A (zh) 2023-04-11 2024-12-16 美商視爾普斯眼科公司 含有酪胺酸激酶抑制劑之眼部植入物
WO2025146683A1 (en) 2024-01-03 2025-07-10 Lyotropic Delivery Systems Ltd. Topical formulations for delivery of an active compound to the back of the eye
WO2025169089A1 (en) 2024-02-05 2025-08-14 Sun Pharmaceutical Industries Limited Ophthalmic compositions of tyrosine kinase inhibitors and their uses

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012150255A1 (en) 2011-05-02 2012-11-08 Dsm Ip Assets B.V. Bis-(alpha-amino-diol-diester) containing polyesteramide for ophtamology
JP2014184348A (ja) 2008-11-17 2014-10-02 Allergan Inc 生分解性α−２アゴニストポリマー性インプラントおよびその治療用途
JP2016502608A (ja) 2012-10-24 2016-01-28 ディーエスエム アイピー アセッツ ビー．ブイ． 薬物送達のためのポリエステルアミドコポリマーを含む繊維
JP2016515618A (ja) 2013-04-01 2016-05-30 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 持続的眼内放出のためのマイクロスフェア薬剤送達システム
JP2017537903A (ja) 2014-12-18 2017-12-21 ディーエスエム アイピー アセッツ ビー．ブイ． 酸感受性薬剤の送達のための薬剤送達系

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2649672C (en) * 2006-05-02 2015-07-07 Medivas, Llc Delivery of ophthalmologic agents to the exterior or interior of the eye
CN102014879A (zh) * 2008-04-25 2011-04-13 帝斯曼知识产权资产管理有限公司 含有具有硫酯键的聚合物的颗粒
KR101699497B1 (ko) * 2010-06-22 2017-01-24 도요보 가부시키가이샤 액정표시장치, 편광판 및 편광자 보호 필름
WO2012092510A2 (en) * 2010-12-29 2012-07-05 I Therapeutics, Llc Ocular drug delivery system
WO2012150265A1 (en) * 2011-05-02 2012-11-08 Dsm Ip Assets B.V. Fiber comprising a biodegradable polymer
US20150037422A1 (en) * 2012-02-22 2015-02-05 Trustees Of Tufts College Compositions and methods for ocular delivery of a therapeutic agent
JP6330815B2 (ja) * 2012-10-02 2018-05-30 ディーエスエム アイピー アセッツ ビー．ブイ． タンパク質および生分解性ポリエステルアミドを含む薬物送達組成物
US20140234389A1 (en) * 2013-02-15 2014-08-21 Allergan, Inc. Sustained drug delivery implant
EP3065703A1 (en) 2013-11-08 2016-09-14 Tyrx, Inc. Polymeric drug delivery system for treating surgical complications
KR20160100992A (ko) * 2013-12-06 2016-08-24 엔비시아 테라퓨틱스 인코포레이티드 눈의 병태의 치료를 위한 전방내 이식물
CA2933900A1 (en) * 2013-12-20 2015-06-25 Georgia Tech Research Corporation Formulations and methods for targeted ocular delivery of therapeutic agents
JP7026507B2 (ja) * 2014-09-06 2022-02-28 インテグラル バイオシステムズ エルエルシー 眼において薬物徐放を達成する方法及び生体適合性組成物
CN115337254A (zh) * 2015-07-23 2022-11-15 爱瑞制药公司 用于治疗眼病的玻璃体内药物递送系统
WO2017120600A1 (en) * 2016-01-08 2017-07-13 Clearside Biomedical, Inc. Compositions and methods of treating wet age-related macular degeneration
US20180117148A1 (en) * 2016-10-28 2018-05-03 Andrew J. Holman Compounds, pharmaceutical compositions and methods of treatments of immune related diseases and disorders
WO2018161035A1 (en) * 2017-03-03 2018-09-07 Macregen, Inc. Treatment of age-related macular degeneration and other eye diseases with one or more therapeutic agents
CN118304422A (zh) 2019-03-05 2024-07-09 爱瑞制药公司 用于治疗眼部疾病或病症的药物组合物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014184348A (ja) 2008-11-17 2014-10-02 Allergan Inc 生分解性α−２アゴニストポリマー性インプラントおよびその治療用途
WO2012150255A1 (en) 2011-05-02 2012-11-08 Dsm Ip Assets B.V. Bis-(alpha-amino-diol-diester) containing polyesteramide for ophtamology
JP2016502608A (ja) 2012-10-24 2016-01-28 ディーエスエム アイピー アセッツ ビー．ブイ． 薬物送達のためのポリエステルアミドコポリマーを含む繊維
JP2016515618A (ja) 2013-04-01 2016-05-30 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 持続的眼内放出のためのマイクロスフェア薬剤送達システム
JP2017537903A (ja) 2014-12-18 2017-12-21 ディーエスエム アイピー アセッツ ビー．ブイ． 酸感受性薬剤の送達のための薬剤送達系

Also Published As

Publication number Publication date
AU2020232314B2 (en) 2023-10-12
EP3934646A4 (en) 2022-12-14
KR20210135560A (ko) 2021-11-15
US12478577B2 (en) 2025-11-25
BR112021017436A2 (pt) 2021-11-16
CN113784727B (zh) 2024-03-29
JP2022523548A (ja) 2022-04-25
MX2025002265A (es) 2025-04-02
JP2025004161A (ja) 2025-01-14
CN118304422A (zh) 2024-07-09
CN118286445A (zh) 2024-07-05
CN113784727A (zh) 2021-12-10
JP2025004160A (ja) 2025-01-14
AU2020232314A1 (en) 2021-09-30
CA3132635A1 (en) 2020-09-10
WO2020181060A1 (en) 2020-09-10
US20200306182A1 (en) 2020-10-01
AU2020232314C1 (en) 2024-03-28
MX2021010599A (es) 2021-12-10
EP3934646A1 (en) 2022-01-12

Similar Documents

Publication Publication Date Title
JP7570342B2 (ja) 眼の疾患又は障害を治療するための医薬組成物
JP5552102B2 (ja) 長時間放出特性を有する生分解性眼インプラント
JP5608138B2 (ja) 生分解性チロシンキナーゼインヒビター硝子体内インプラント
TWI377956B (en) Biodegradable intravitreal tyrosine kinase implants
JP6570513B2 (ja) 持続的眼内放出のためのマイクロスフェア薬剤送達システム
US11116776B2 (en) Intravitreal drug delivery systems for the treatment of ocular conditions
JP2020062381A (ja) 治療薬剤の持続放出のための薬物コア
JP2014014694A (ja) 血管拡張薬を含有する持続放出性眼内インプラント
JP2016540055A (ja) 眼性状態を処置するための前房内インプラント
JP2013035874A (ja) α−２アドレナリン受容体アゴニスト含有生分解性眼内インプラント
MX2011009901A (es) Sistemas de administracion intraocular de farmacos de liberacion sostenida y metodos para tratar afecciones oculares.
JP2007535367A (ja) エストラジオール誘導体またはエストラトポン誘導体を含有する徐放性眼内インプラント、ならびに関連する製造法
CN120897764A (zh) 包含阿西替尼多晶型物iv的眼部植入物
BRPI0604577B1 (pt) formulação farmacêutica para administração intraocular de fármacos e processo de obtenção
AU2016269432A1 (en) Biodegradable introcular tyrosine kinase inhibitor implants

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230228

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240708

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240910

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241008

R150 Certificate of patent or registration of utility model

Ref document number: 7570342

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350